-
-
-
-
-
-
-
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
-
-
-
-
-
-
PTC Therapeutics' 2023 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
-
-
-
-
-
-
-
Upstazaâ„¢ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA
-
-
-
-
-
-
-
PTC Therapeutics (PTCT) Misses Q1 EPS by 32c, Revenues Beat
-
-
-
-
-
-
-
Royalty Pharma Acquires Royalty Interest in Risdiplam From PTC Therapeutics
-
-
-
-
-
-
-
PTC Therapeutics Launches Sixth Annual STRIVE Awards Program for Advocacy Organizations in Duchenne Muscular Dystrophy
-
-
-
-
-
-
-
PTC Therapeutics Announces Results from Long-Term AADC Deficiency Gene Therapy Treatment Demonstrating Sustained Improvements
-
1,185,412 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

